TITLE

A clinical, renal and immunological assessment of Surface Modifying Additive Treated (SMARTâ„¢) cardiopulmonary bypass circuits

AUTHOR(S)
Allen, Stephen; McBride, William T.; Young, Ian S.; MacGowan, Simon W.; McMurray, Terence J.; Prabhu, Sachin; Penugonda, S. Prasad; Armstrong, Marilyn A.
PUB. DATE
September 2005
SOURCE
Perfusion;Sep2005, Vol. 20 Issue 5, p255
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Biocompatible cardiopulmonary bypass (CPB) circuits aim to reduce contact activation and its physiological consequences. We investigated the hypothesis that use of Surface Modifying Additive (SMA)-treated circuits (Sorin Group Ltd) compared with non-SMA circuits would be associated with preservation of blood pressure during CPB and modulation of perioperative subclinical renal function (urinary α-1-microglobulin (α-1-m)) and plasma and urinary cytokine changes. In a study of low-risk CABG patients (n=40), randomized to SMA (n=20) versus non-SMA circuits (n=20), we found better preserved blood pressure at CPB initiation in SMA patients (p<0.05), particularly in ACE-inhibited SMA patients (n=11) versus ACE-inhibited non-SMA patients (n=10) (p<0.05). Plasma anti-inflammatory IL-10, as well as urinary α-1-m, were elevated 48 hours post-operatively (p<0.05). SMA patients also had lower blood loss (p<0.05). SMA circuits have some clinical benefit, especially in ACE-inhibited patients.
ACCESSION #
18281902

 

Related Articles

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics